ORCID
- CB Carroll: 0000-0001-7472-953X
Abstract
In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.
Publication Date
2018-07-05
Publication Title
Neurodegenerative Disease Management
ISSN
1758-2024
Embargo Period
2018-08-03
Recommended Citation
Carroll, C., Fackrell, R., Grosset, D., Mohamed, B., Reddy, P., Parry, M., Chaudhuri, K., & Foltynie, T. (2018) 'Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists', Neurodegenerative Disease Management, . Retrieved from https://pearl.plymouth.ac.uk/pms-research/139
